Blog April 3, 2019
Claim Interpretation for Expired Patents
- Person title
Written by Stuart Nelson
Claim construction is a key issue in post-grant proceedings, and the application of the "broadest reasonable construction" standard is receiving increased attention. Recently in Amkor Technology, Inc. v. Tessera, Inc. (IPR2013-00242), the patent owner filed a terminal disclaimer such that the disputed patent would be effectively expired. Order, Apr. 14, 2014, p. 3. The patent owner argued that while the broadest reasonable construction applies to unexpired patents in inter partes review, claims of an expired patent should be interpreted with an analysis similar to that of a district court. Id. at 2. The patent owner now seeks "to file a motion to terminate the proceeding on the basis that the Board applied the broadest reasonable interpretation standard in the decision to institute this inter partes review." Id. at 2. It should be noted that the patent owner's position is not that the proceeding should be terminated simply because the patent is now expired, but because the proper claim construction has now changed. The petitioner opposes and the Board has requested detailed briefing on what it considers an issue of first impression. Id. at 3-4. The parties have briefed the matter, but no decision has been issued.
An unrelated case also dealt with claim construction of an expired patent, but in a different way. In Toyota Motor Corp. v. LeRoy G. Hagenbuch (IPR2013-00483), the disputed patent expired during the inter partes review proceeding just ten days after the decision to institute. Order, April 16, 2014, p. 2. During a conference call, both the petitioner and the patent owner "agreed that BRI should not be applied in the final decision" and that "the claims should be construed in a fashion similar to that used in a district court's review." Id. The Board then proceeded to construe a disputed claim term using "the proper non-BRI construction," but ultimately construed that term the same way as under the broadest reasonable interpretation. Id. at 2-3.
It will be interesting to see what the Board does with this issue in Amkor Technology, Inc. v. Tessera, Inc. as well as other cases. In the meantime, patent owners unhappy with claim interpretations during post-grant proceedings may increasingly consider the possibility of patent expiration, whether by the patent's term naturally running out or via a terminal disclaimer. However, filing a terminal disclaimer may prove risky, especially for patents with substantial term remaining, as there is no guarantee that the Board will apply a narrower construction.
For information, contact Stuart Nelson or another member of Fish’s post-grant practice.
The opinions expressed are those of the authors on the date noted above and do not necessarily reflect the views of Fish & Richardson P.C., any other of its lawyers, its clients, or any of its or their respective affiliates. This post is for general information purposes only and is not intended to be and should not be taken as legal advice. No attorney-client relationship is formed.
Article May 9, 2016
From Testimonial Evidence to Word Count: All Change at the PTAB
Blog March 30, 2016
New Rules for Post-Grant Proceedings
Blog March 17, 2016
Use of the Wayback Machine in IPR Is Under Attack
Blog August 5, 2014
Requests for Rehearings are Rarely Granted
Blog July 21, 2014
Additional Discovery Ordered for Application File History
Blog May 28, 2014
A Late Terminal Disclaimer Does Not Change the Claim Interpretation Standard
Blog May 22, 2014
Sur-Replies Can Be Permitted in Post-Grant Proceedings
Blog April 29, 2014
Excluding Reply Declarations and Evidence
Article November 21, 2023
Strategic Use of Evidence at the Patent Trial and Appeal Board
Article November 17, 2023
Why the Effect of Vivint Has Been Minimal
Blog October 17, 2023
USPTO Issues Proposed Rules on Pre-Issuance Internal Circulation and Review of PTAB Decisions
Article October 13, 2023
Eleven Ways the PREVAIL Act Would Alter PTAB Practice
Blog October 2, 2023
What’s New in Director Review?
Blog April 26, 2023
Legal Alert: USPTO Issues Advance Notice of Proposed Rulemaking for PTAB Proceedings
Blog January 17, 2023
Biosimilars 2022 Year in Review
Article December 22, 2022
Attorneys Dorothy Whelan, Karl Renner, and Casey Kraning, Ph.D., Author National Law Journal Article "A Look Back on a Decade of Practice at the PTAB"
Article October 20, 2022
Life Sciences Entrepreneur Sourcebook | Intellectual Property: What It Is and Why You Should Care
Article October 5, 2022